
Anticoagulation Forum/X
Jun 2, 2025, 08:35
Refining Thrombophilia Testing: New ACE Rapid Resource Offers Practical Guidance for Clinicians – Anticoagulation Forum
The Anticoagulation Forum has released a new ACE Rapid Resource shared on X, offering concise, evidence-based guidance on thrombophilia testing, built on the most current clinical guidelines. This resource supports clinicians across a range of scenarios—from determining the appropriateness of testing to accurately interpreting results.
“Key features include:
Indications for Testing: Defines clinical contexts where thrombophilia testing is justified, helping to prevent overuse and reduce diagnostic errors.
Interpretation Framework: Offers expert-driven explanations on how to interpret test results in the presence of confounding factors such as acute illness, medications, pregnancy, or hormonal therapy.
Clinical Application: Equips healthcare providers with actionable insights to improve diagnostic accuracy and enhance patient outcomes in suspected thrombophilia.
This resource is a collaboration led by Greg Hadlock, PharmD, PhD, with clinical input from Jean Connors, MD, and an expert panel, and is part of a growing library of high-quality tools offered by the Anticoagulation Forum.”
Access the full resource on ACE Rapid Resource – Thrombophilia Testing․
Thrombophilia Testing: Key Insights from the ACE Rapid Resource
The Anticoagulation Forum’s ACE Rapid Resource offers a streamlined, evidence-based summary to guide clinicians on when and how to perform thrombophilia testing. It emphasizes:
- Appropriate indications to avoid unnecessary testing and misinterpretation.
- Result interpretation in the context of confounding factors such as acute illness, medications, and pregnancy.
- Clinical integration to support accurate diagnosis and optimize patient outcomes.
- This resource reflects current best practices and is intended to enhance decision-making in complex thrombotic risk assessments.
Discover the latest expert insights in Hemostasis Today.
-
Jul 23, 2025, 15:42Uncovering the Hidden Signs of von Willebrand Disease
-
Jul 22, 2025, 17:19Wolfgang Miesbach Shares Newly Released Gene Therapy Qualification Criteria Paper
-
Jul 22, 2025, 17:05EAHAD Launches Europe-Wide Survey on Haemophilia Gene Therapy Readiness
-
Jul 22, 2025, 09:26Hemophilia of Georgia Highlights Participation in WFH 2025 Summit and Global Youth Training
-
Jul 22, 2025, 08:55tPA in Action: Quick‑Guide to Alteplase Dosage for Common Thrombotic Emergencies
-
Jul 22, 2025, 09:17Decoding Antiphospholipid Syndrome: Why Triple Positivity Is a Red Flag for Thrombosis
-
Jul 21, 2025, 16:24Code I26: A Precise Tool to Strengthen VTE Surveillance
-
Jul 20, 2025, 17:12Thromboelastography: Coagulation Beyond INR and aPTT
-
Jul 20, 2025, 16:555 Crucial Insights into Low VWF QL: Uncovering a Distinct Cause of Bleeding
-
Jul 19, 2025, 17:16Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 23, 2025, 15:34Don't Miss the Hemophilia B Virtual Event on July 29 – Sign Up Now!
-
Jul 23, 2025, 11:05Haemnet Gives Voice to Parents Facing the Challenges of Childhood Bleeding Disorders
-
Jul 23, 2025, 10:43From Blood Clot Survivor to NFL History: Trey Smith’s Record Deal
-
Jul 22, 2025, 16:48How Children See Blood Clots: World Thrombosis Day Shares Artwork from Young Artists
-
Jul 22, 2025, 08:48NBCA: From Marathon Dreams to ICU — Sam’s Blood Clot Wake-Up Call
Jul 23, 2025, 15:42
Jul 23, 2025, 15:34
Jul 23, 2025, 15:31
Jul 23, 2025, 10:59
Jul 23, 2025, 10:43
Jul 22, 2025, 17:05